Clinical Trials Logo

Ocular Hypertension clinical trials

View clinical trials related to Ocular Hypertension.

Filter by:

NCT ID: NCT01026831 Completed - Ocular Hypertension Clinical Trials

Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)

Start date: January 2010
Phase: Phase 3
Study type: Interventional

This study was to compare the safety and efficacy of the preservative-free formulation of 0.0015% MK2452 (tafluprost) and preservative-free 0.5% timolol maleate in patients with open-angle glaucoma and ocular hypertension. This study was to demonstrate that the preservative-free formulation of 0.0015% tafluprost is non-inferior to preservative-free 0.5% timolol maleate.

NCT ID: NCT01016691 Completed - Ocular Hypertension Clinical Trials

Safety and Efficacy of a Drug Delivery System in Glaucoma

Start date: October 2009
Phase: Phase 2
Study type: Interventional

Evaluation of the ocular safety and efficacy of a drug delivery system in open-angle glaucoma or ocular hypertension.

NCT ID: NCT01012245 Completed - Glaucoma Clinical Trials

Non-Interventional Study In Patients With Ocular Hypertension And Open Angle Glaucoma Treated With Xalatan And Xalacom

XCHANGE
Start date: January 2000
Phase:
Study type: Observational

Non-interventional study to obtain real life data from the treatment with Xalatan and Xalacom in Germany and to assess the long-term efficacy and tolerability under routine conditions. Data were entered into an electronic case report form.

NCT ID: NCT01001195 Completed - Ocular Hypertension Clinical Trials

Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

Start date: November 2009
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety, efficacy and dose-response of AGN-210669. This study will also compare AGN-210669 with bimatoprost ophthalmic solution (LUMIGAN®).

NCT ID: NCT00990743 Completed - Glaucoma Clinical Trials

Tolerance and Effect on Intraocular Pressure After Administration of SYL040012

Start date: September 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether SYL040012 is safe for the treatment of ocular hypertension and glaucoma.

NCT ID: NCT00972426 Completed - Glaucoma Clinical Trials

A Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients

Start date: October 2009
Phase: Phase 4
Study type: Interventional

The primary objective of the clinical study is to evaluate the efficacy and safety for Mikelan LA eye drops 2% (once per day) of intra-ocular pressure decreased.

NCT ID: NCT00967811 Completed - Glaucoma Clinical Trials

A Study of Different Formulations of the L-PPDS in Subjects With OH or OAG

Start date: August 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and preliminary efficacy of two formulations of the Latanoprost-PPDS in subjects with ocular hypertension or open-angle glaucoma.

NCT ID: NCT00950690 Completed - Glaucoma Clinical Trials

Efficacy and Tolerability of Xalatan in Patients

A6111128
Start date: July 2005
Phase:
Study type: Observational

Efficacy data was not collected or analyzed. This study did assess safety and tolerability of Xalatan.

NCT ID: NCT00947661 Completed - Ocular Hypertension Clinical Trials

Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension

Start date: July 2010
Phase: Phase 3
Study type: Interventional

A single-blind , 12-week, parallel group clinical study is planned to evaluate the efficacy and safety of SPARC0912 and Reference0912. SPARC0912 is an experimental drug having similar active ingredient but containing a different preservative as that in Reference0912. Patients with open angle glaucoma or ocular hypertension will be enrolled and randomly assigned to receive either product. One drop will be instilled to the study eye nightly at 8:00 PM.

NCT ID: NCT00945958 Completed - Ocular Hypertension Clinical Trials

Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension

Start date: November 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the long-term safety of SPARC0913. A multicenter, open label, non-randomized, uncontrolled, single group assignment, safety study of subjects with primary open angle glaucoma or ocular hypertension is planned. Subjects will receive study medication for a period of 24-weeks.